



1st Live Webinar – Thematic Network

Standards of Care: HIV, VH, and TB

Good Practices and Ensuring Prevention
& Care for People on the move



Good practices in implementation and cross-border healthcare: Access to quality care/prevention for displaced persons

Miłosz Parczewski M.D. Ph.D.

Head: Department of Infectious, Tropical Diseases and Immune Deficiency,
Pomeranian Medical University in Szczecin, Szczecin, Poland

EACS: Vice-President

Polish AIDS Society: President

16th February 2023


Issues in access to quality care and prevention in HIV/Hepatitis/TB/STI

- Maintain high ARV treatment efficacy in displaced persons
- Respond to the needs related to population characteristics change
- Timely diagnosis of HIV/HCV/HBV/TB/STI
- Vaccination programmes (HBV, COVID-19, MMR)
- Access to TB drugs in case of MDR/XDR
- Surveillance and access to HIV drug susceptibility/resistance testing

Antiretroviral treatment data

ART in Ukraine

ART in Poland



2NRTI+EFV
8.1%

Challenge: Variable TLD availability and frequent need for the within-class antiretroviral treatment change

TLD
70.3%

TDF/FTC + DTG
41.7%

TAF/FTC/BIC
34.3%

TAF/FTC+DTG
8.7%

Clinical data for Ukrainian migrants entering HIV care in Poland

Median age: 40 (IQR:34-45) years

70.1% of patients female

89.1% initiated ART in Ukraine
10.9% diagnosed in Poland (underreported)

10.1% self reported previous TB infection

Median lymphocyte CD4 count at care entry:
561 (IQR: 350-755) cells/ μ l (n=531)

MODE OF HIV ACQUISITION

■ Heterosexual ■ PWID

Challenge:
Integrated services especially gynecological and obstetric care, contraception, pregnancy management. Language barrier of key importance (sensitive care/fear of stigma)

71%

Ukrainian migrants newly diagnosed with HIV in Poland (n=104)

Median age: 37 (IQR:30-43) years

55.7% female

Median lymphocyte CD4 count at diagnosis:
184 (IQR: 27-389) cells/ μ l

Median HIV-1 viral load at diagnosis: 5.23
(IQR: 4.49-5.57) log copies/ml

22.1% - Anti-HCV (+), 4.2% HBs Ag (+)

12.4% - VDRL (+)

77.3% diagnosed late

Tuberculosis*

Challenges:

- expansion of targetted testing services including home based
- non-disclosure of MSM populations (stigma) \rightarrow subptimal STI testing
- Access to TB drugs (reinforcement of national programmes)

Cytomegaloviral retinitis 1 (2.6%)

Syrian refugees in Turkey: hepatitis

- Hepatitis serology (n=473)

Median age 34
(range 17-82) years

Anti Hbc total: 23.9%

Table-4: Distribution of Syrian refugees according to HBsAg, Anti-HBs, Anti-HBc total and Anti-HCV status

	Positive		Negative	
	Number	%	Number	%
HBsAg	8	1.7	465	98.3
Anti-HBs	119	25.2	354	74.8
Anti-HBc total	113	23.9	360	76.1
Anti HCV	2	0.4	471	99.6
Immunized with the vaccine	34	7.1	439	92.9

Syrian Refugees at Risk of Hepatitis Diseases in Turkey, in Şanlıurfa?

Zehra KEKLIK¹, İbrahim KORUK², Şule ALLAHVERDİ^{3*}

¹Ministry of Health, Provincial Health Directorate Şanlıurfa, 63300, Turkey

^{2,3}Harran University Faculty of Medicine, Department of Public Health, Şanlıurfa, 63300, Turkey

Issues in hepatitis care access

Hepatitis markers among Ukrainian migrants with HIV (Poland)

**Hbs Ag (+)
2.9%**

Anti-Hbc (+) in
31.6%

**Anti-Hbs >10 IU/ml
only in 18.2%!**

Challenges:

- outreach of HBV vaccination programmes
- Integrated access to HCV/HBV treatment
- Testing programmes for refugees

Germany: hepatitis markers in immigrant populations (n=1313)

many from Eastern Europe, 12.0% EE

hepatitis B core antibodies.

5% of patients.

HBV DNA detected in 2.2% cases

Issue of HIV drug resistance

Patient ID	Age	Gender	ARV exposure	Subtype	NRTI DRMs	NNRI DRMs	PI DRMs	InI DRMs
1666	44	Female	TDF/3TC/EFV	A6		E138G	None	None
46uk	47	Female					None	None
97	35	Female					None	None
SV180274	48	Male					M46I, V82S	None
1732	48	Male			M184V,I215F	I90S	None	E138K,Q148R,R 263K
36uk	41	Female	TDF/3TC/EFV	A6	None	K101E,E138G	None	None
1601	58	Female	TLD	A6	M184MV			
1715	43	Male	TLD	A6	None	V106I,Y188YC	None	None

Challenges:

- Access to drug resistance testing poor in CEE
- Small number of emerging drug resistance
- Surveillance on subtype variability (A6) and introductions

Action points

- Maintenance of stable access to inexpensive DTV based regimens
- Expanding specialist Obstetrics & Gynecology care (urgent)
- Development of the implementation programmes for HIV/Hepatitis/STI testing and for displaced populations (divergent culture based needs).
- Implementing vaccination access (e.g. HBV, COVID-19, MMR)
- Expansion of TDF/FTC based PreP programmes
- Integration of HIV resistance surveillance capacities at European level
- System capacity assessment in progress (Poland)



1st Live Webinar – Thematic Network

Standards of Care: HIV, VH, and TB

Good Practices and Ensuring Prevention
& Care for People on the move



THANK YOU

Good practices in implementation and cross-border healthcare: Access to quality care/prevention for displaced persons

Miłosz Parczewski M.D. Ph.D.

Head: Department of Infectious, Tropical Diseases and Immune Deficiency,
Pomeranian Medical University in Szczecin, Szczecin, Poland

EACS: Vice-President

Polish AIDS Society: President

16th February 2023